Tag: Johnson & Johnson

J&J, Actelion End Speculation With $30B Hook Up

J&J, Actelion End Speculation With $30B Hook Up

After negotiations dating back to August, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Swiss biopharma Actelion (SIX: ATLN) for $280 per share in cash (about CHF280), far outstripping Morningstar’s fair-value estimate of CHF112. J&J plans to use US […]